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Natural killer (NK) cells are important effectors of innate immunity that play a critical role
in the control of human viral infections. Indeed, given their capability to directly recognize
virally infected cells without the need of specific antigen presentation, NK cells are on the
first line of defense against these invading pathogens. By establishing cellular networks
with a variety of cell types such as dendritic cells, NK cells can also amplify anti-viral adap-
tive immune responses. In turn, viruses evolved and developed several mechanisms to
evade NK cell-mediated immune activity. It has been reported that certain viral diseases,
including human immunodeficiency virus-1 as well as human cytomegalovirus infections,
are associated with a pathologic redistribution of NK cell subsets in the peripheral blood. In
particular, it has been observed the expansion of unconventional CD56neg NK cells, whose
effector functions are significantly impaired as compared to that of conventional CD56pos
NK cells. In this review, we address the impact of these two chronic viral infections on the
functional and phenotypic perturbations of human NK cell compartment.
Keywords: viral infection, immune escape, immune activation, innate immune response, physiophysiological
interaction
INTRODUCTION
In the absence of drugs that are able to eradicate and cure viral
infections, the presence of efficient immune responses is key in
the control and clearance of virally infected cells. Natural killer
(NK) cells represent the first line of defense against viral infec-
tions, as it became clear since the first experimental evidence in
the late 1980s reporting severe and recurrent herpes virus infec-
tions in a young patient with NK cell deficiency (1). The fact that
NK cells do not need a prior antigen sensitization makes them
ready to fight against pathogens starting from the early phases
of innate immune responses through several effector functions
controlled by a dynamic balance between inhibitory and acti-
vating NK cell receptors (NKRs) (2). Indeed, NK cells are able
to lyse “non-self” cellular targets while sparing normal cells that
express adequate levels of “self” major histocompatibility com-
plex of class I (MHC-I) molecules. This cytolytic function is
regulated by a heterogeneous family of inhibitory NKRs (iNKRs)
that bind specifically to either classical or non-classical human
leukocyte antigen (HLA) alleles (3). Diminution or absence of
expression of HLA-I molecules on the surface of virally infected
cells results in reduced engagement of iNKRs which, in turn, allow
a large group of activating NKRs (aNKRs) to trigger cytotoxic-
ity. The “on signal” exerted by aNKRs to trigger NK cell killing
depends on the induced expression of putative ligands for acti-
vating receptors on virally infected target cells. The recognition
of these specific ligands is required for the engagement of aNKR-
mediated downstream pathways associated with the NK cell release
of lytic granules (4–13).
Upon activation,NK cells also produce several chemokines such
as CCL3/MIP1α, CCL4/MIP1β CCL5/RANTES, and cytokines
such as interferon-γ (IFN-γ), tumor necrosis factor (TNF), and
granulocyte/macrophage colony-stimulating factor (GM-CSF).
These soluble factors play not only an important regulatory role in
hematopoiesis and cellular activation, but are also involved in the
suppression of human immunodeficiency virus-1 (HIV-1) repli-
cation through non-cytolytic mechanisms (2, 10, 14–17). NK cells
are also endowed with the ability of either priming or taking part
to cellular networks of interactions. In fact, it has been shown
that NK cells are engaged in an active and bi-directional cross
talk with autologous dendritic cells (DCs) through a process that
requires both NK cell–DC cellular interactions and secretion of
specific cytokines (18–25). Furthermore, monocytes/macrophages
and neutrophils have been shown to regulate the recruitment and
the activation of NK cells, which, in turn, can eliminate over-
stimulated macrophages (26–29). It has been also reported that
human neutrophils are able to establish a network with both NK
cells and 6-sulfo LacNAc+ DCs (slanDC). This “mènage à trois”
involves direct reciprocal interactions as well as positive amplifi-
cation loops mediated by cell-derived cytokines with the aim of
inducing IFN-γ production by NK cells (30). The final outcome of
www.frontiersin.org August 2014 | Volume 5 | Article 390 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lugli et al. NK cells and viral infections
these synergic NK cell interactions is the coordination and opti-
mization of both innate and adaptive immunity in response to
inflammatory stimuli such as viral infections at tissue sites (31).
Under physiological conditions, the distribution of the
surface markers CD56 and CD16 (FcγRIII) defines two
subsets of CD14neg/CD3neg/CD19neg NK lymphocytes: the
CD56bright/CD16neg-dim (CD56bright) population that accounts for
~10% of blood NK cells and the CD56dim/CD16bright (CD56dim)
cells that comprise for ~90% of circulating NK cells (17, 32).
CD56bright NK cells exert only marginal cytotoxic capacity and
yet produce high amounts of cytokines like IFN-γ, TNF, and GM-
CSF. Their degree of proliferation in response to activation stimuli
is much higher as compared to that of CD56dim NK cells. Given
the pleiotropic roles of the cytokines on multiple immune and
non-immune populations, CD56bright NK cells have been gener-
ally referred to as regulatory NK cells. Conversely, CD56dim NK
cells were originally identified as the main subset endowed with
cytotoxic capacity, although subsequent works indicated that they
can also produce relatively high amounts of pro-inflammatory
cytokines following the engagement of aNKRs (32–36). The dif-
ferent functional outcomes of CD56bright and CD56dim NK cells
are associated with different repertoires of NKRs and with distinct
homing capacities that are determined at the level of chemokine
receptor expression on the cell surface. Indeed, CD56dim NK cells
preferentially migrate to inflamed peripheral tissues on the basis
of their increased expression of CXCR1, CX3CR1, and ChemR23,
while the CD56bright subset expressing CCR7 preferentially homes
to secondary lymphoid organs (37–39). Remarkably, recent data
indicate that, in several pathological conditions including viral
infections, CD56dim NK cells may also express CCR7 de novo and
migrate toward lymph nodes (40–42).
It is well known that viruses remarkably affect NK cell home-
ostasis, phenotype, and functions, thus highlighting the key roles
played by NK lymphocytes in the physiopathology of chronic and
inflammatory viral disorders. This review provides an updated
summary of the virally induced changes of NK cell phenotype
and functions and of their implications in NK cell physiology and
physiopathology.
NK CELL RESPONSES TO HIV-1
HIGH FREQUENCIES OF CD56neg NK CELL SUBSET IN HIV-1 INFECTION
Although the NK cell population is mainly composed by the
two CD56bright and CD56dim subsets, low frequencies of a
CD14neg/CD3neg/CD19neg/CD56neg/CD16bright (CD56neg) popu-
lation are also detected in healthy donors (16, 43). This unusual
and rare population has been substantially ignored until mid
1990s, when it has been described that the decrement of absolute
numbers of circulating NK cells during the course of HIV-1 infec-
tion is associated with expansion of an unconventional subset of
CD56neg NK lymphocytes (44). This report opened a new research
topic in the field of NK cell biology and many groups, including
ours, highlighted the great importance of CD56neg NK cell in the
physiopathology of HIV-1 infection. It then became evident that
NK cells are remarkably affected by the deleterious effect of ongo-
ing HIV-1 replication. Although NK cells are not productively
infected by HIV-1, high and chronic levels of viremia significantly
impair NK cell-mediated host immune responses, thus leading to
a defective control of viral spreading and, subsequently, to disease
progression. This is due, at least in part, to the defective capaci-
ties of NK cells from viremic HIV-1-infected patients to eliminate
autologous HIV-1-infected CD4pos T cells. Moreover, NK cells
from the same individuals displayed impaired killing of cell targets
either tumor-transformed or infected by opportunistic pathogens
as well as weaker production of anti-viral cytokines/chemokines
and defective interactions with autologous DCs (10, 17). In turn,
dysfunctions in NK-DC crosstalk impair the maturation of DCs
that, instead of priming an effective adaptive immune response
by presenting HIV-1 antigens to T cells, contribute to disseminate
the infection in secondary lymphoid organs (23). These NK cell
aberrancies are a direct consequence of the HIV-1-driven expan-
sion of the highly anergic CD56neg NK cell subset. In patients
with chronic or late stage HIV-1 infection and high viral loads,
decreased frequencies of CD56dim/CD16pos NK cell populations
are counterbalanced by increased percentages of these dysfunc-
tional CD56neg cells expressing an aberrant repertoire of inhibitory
and aNKRs. This experimental evidence clarified that, rather than
an absolute decrement of total circulating NK cells (44), HIV-1
viremia is associated with a significant and pathological redis-
tribution of NK cell subsets associated with impaired anti-viral
responses (12, 16, 23, 45–53). The sequential deregulation of NK
cell subset has been reported to start from the early phases of
HIV-1 infection due to the presence of surface markers highly
sensitive to viral replication (33, 53). In particular, it has been
reported that the c-lectin-type molecule Siglec-7 (also known as
p75/AIRM1), an inhibitory receptor constitutively expressed on
all NK cells, is the first marker to be down-regulated during the
early phases of HIV-1 infection before the loss of CD56. Siglec-
7 down-modulation is preserved throughout the course of the
infection and depends on the level of viral replication. Indeed,
the small cohort of individuals that do not progress toward AIDS
(i.e., the long-term non-progressors) and who naturally display
low or undetectable HIV-1 viremia keep a normal distribution
of NK cell subsets as identified by the expression of Siglec-7 and
CD56. Since all these NK cell phenotypic and functional abnor-
malities are reversible following a successfully suppression of viral
replication, the pathological redistribution of NK cell subsets can
also be used to monitor the effectiveness of antiretroviral therapy
(ART) (17).
Finally, we recently reported that the NK cell modulation of
Siglec-7 in HIV-1 infection is directly involved in HIV-1 patho-
genesis (54). In fact, chronic high levels of viral replication lead to
a decreased surface expression of Siglec-7 on NK cells counterbal-
anced by increased levels of soluble Siglec-7 detected in the plasma
of viremic HIV-1-infected patients. This soluble form of Siglec-7
is able to directly bind the glycoprotein 120 expressed on HIV-1
envelope and facilitates the infection of Siglec-7neg/CD4pos T cells.
In contrast, high levels of HIV-1 viremia do not alter the constitu-
tive expression of Siglec-7 in monocytes and macrophages, whose
susceptibility to HIV-1 infection is enhanced by the direct inter-
action between the virus and this lectin-type receptor (33, 54).
These data suggest that, similar to other members of Siglec fam-
ily (55–57), both membrane-bound and soluble Siglec-7 greatly
increase the susceptibility of CD4pos cell targets expressing CCR5
or CXCR4 to be infected by HIV-I (54).
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ORIGIN OF THE CD56neg NK CELL SUBSET
Natural killer cells resulted not to be directly infected by HIV-1
(45) and, therefore, it is unlikely that the expansion of CD56neg
NK cell is HIV-1 specific. Indeed, although the origin of CD56neg
cells is still being debated, it later became clear that high frequen-
cies of this pathological subset are associated with the presence
of chronic and systemic inflammation, which is a hallmark of
chronic HIV-1 infection (10, 12). Several studies then investigated
other human disorders characterized by high levels of systemic
immune activation and reported similar increased percentages
of circulating CD56neg NK cells. Among these diseases, there
are hepatitis C virus (HCV) (58, 59), human cytomegalovirus
(HCMV) (60), hantavirus (61), treponema pallidum (62) infec-
tions, post-transplant lymphoproliferative malignancies driven by
Epstein–Barr virus (EBV), (63) and autoimmune disorders such
as myasthenia gravis (64) and dermatomyositis (65). Expansion
of CD56neg NK cells has been described both in HCV as well as
in HCV–HIV co-infected patients (59). However, the increase of
this aberrant subset is much more contained in mono-infection
by HCV compared to HCV–HIV co-infection. Therefore, addi-
tional studies are required to clarify whether the accumulation of
CD56neg NK cells is a hallmark of chronic HCV infection. Finally,
a significant proportion of CD56neg cells have also been found in
umbilical cord blood and in healthy infants and are characterized
by impaired anti-viral activities (66–69).
The fact that high frequencies of CD56neg NK cells are found in
so many different either pathological or physiological conditions
underline that their ontogenesis relies on mechanism(s) associated
with activation of the immune system and not with a specific viral
infection or inflammatory disorder. Moreover, in all the above-
mentioned disorders as well as in umbilical cord blood, CD56neg
cells share the same phenotypic and functional features: (i) low
expression of natural cytotoxity receptors (NCRs) and Siglec-7;
(ii) reduced cytolytic potential; (iii) decreased production of anti-
viral cytokines and chemokines. In regard to their ontogeny, it has
been first postulated that this “anergic” CD56neg cells could arise
from a failure of NK cell development and/or from inadequate cell
stimulation. This theory was mainly supported by experimental
evidence showing that the incubation in vitro of CD56neg cells
with IL-2, IL-12, and IL-15 induces cell proliferation and restores
the classical distribution of CD56 and repertoire of NKRs (44,
59, 67). We have to point out though that therapies with anti-viral
drugs (in case of HIV-1 and HCV infections) or with immunosup-
pressants (for myasthenia gravis and dermatomyositis) restored
physiological NK cell phenotype and functions (16, 59, 64, 65).
Unfortunately, there are no reports showing that an in vitro set-
ting could reproduce the expansion of CD56neg cells and this ham-
pered our capacity to disclose the mechanistic insights highlighting
this phenomenon. Our current knowledge of NK cell ontogenesis
states that CD16neg immature NK (iNK) cells expressing low levels
of CD56 and NCRs precede CD56bright NK cells in development
(43, 70). Although sharing these phenotypic features with iNKT,
CD56neg NK cells also express many NK cell-specific receptors
that are not found on iNK cells, including KIRs, CD94/NKG2A,
NKG2D and CD16 (10, 43). iNK cells produce high amounts of
GM-CSF but not other inflammatory cytokines following phor-
bol myristate acetate (PMA)/ionomycin stimulation, and they are
not even able to kill target cells nor to produce cytokines (70).
Moreover, iNK cells develop into CD56bright NK cells after stimu-
lation with IL-15, thus suggesting they are precursors of these cells
in vivo (70). On the contrary, CD56neg NK cells retain inflamma-
tory cytokine production and killing capacity, albeit at impaired
level compared to conventional CD56pos NK cells (10, 17). Finally,
CD56neg cells but not iNK cells have been recently shown to
express CD57 (71), a marker of terminal cell differentiation (72).
Taken together, these experimental findings strongly suggest that
CD56neg NK cells do not derive from iNK cells.
An alternative hypothesis proposed that CD56neg NK cells are
mature lymphocytes that recently engaged target cells. Under nor-
mal circumstances, NK cells are capable of killing multiple target
cells, thus resulting in a reduced, but never complete, loss of per-
forin and granzyme B (73). In HIV-1-infected patients, decreased
granzyme B and perforin expression and increased surface expres-
sion of CD107a in the absence of ex vivo stimulation suggests that
CD56neg NK cells engage target cells in vivo. Authors also argued
that this hypothesis is further supported by the increased expres-
sion of CD95 on CD56neg cell subset, thus indicating a more pro-
nounced activation compared to their CD56dim cell counterpart
(71). However, the down-regulation of CD56 as a consequence of
recent activation is still awaiting confirmation by additional stud-
ies. Since the transcriptome of CD56neg NK cells has been found
to be more similar to myeloid cells than to traditional CD56dim
NK cells (74), CD7, a surface protein expressed on thymocytes
and mature T cells, has been proposed as an additional informa-
tive marker for their identification. In this regard, CD56neg NK
cells have been reported to be a mixed population of CD7pos true
NK cells and CD7neg myeloid cells present at a low frequency in
healthy donors and expanded in HIV-1 viremic subjects (71).
NK CELL RESPONSES TO HUMAN CYTOMEGALOVIRUS
Similar to what it has been observed in humans (1), mice infected
with murine cytomegalovirus (MCMV) and depleted of NK
cells were unable to control infection and displayed dissemi-
nated MCMV in the lungs and in the liver (75). The anti-viral
NK cell responses are particularly relevant when viruses exploit
mechanisms of immune evasion, leading to the down-regulation
of MHC-I molecules and thus escape from the CD8pos T cell-
mediated cytolytic activity. Multiple HCMV-derived proteins have
been demonstrated to interfere with the transport or the expres-
sion of MHC-I on the cell surface (76). On the other hand, HCMV-
infected cells up-regulate ligands for the aNKR NKG2D, including
MICA, MICB, and UL-16 binding proteins (ULBPs), thereby facil-
itating NK cell activation (77–79). On average, 50–80% of the
human population in Western countries is HCMV-infected, but
the virus does not harm the health of immune-competent individ-
uals, unless in specific situations such as maternal HCMV reacti-
vation or primary infection during pregnancy. Instead, immune-
compromised individuals, such as those infected with HIV-1 or
those who received bone marrow transplantation (BMT), are par-
ticularly susceptible to CMV reactivation (80). Following BMT,
NK cells recover faster than CD8pos T cells (2–3 weeks vs. 4–
6 weeks, depending on the type of transplantation) and possibly
mediate a first line of protection against viral dissemination (81).
Different groups have recently shown that patients experiencing
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HCMV reactivation following BMT display highly mature KIRpos,
NKG2Aneg, NKG2Cpos, and CD57pos NK cells that are not found
in uninfected recipients (82–84). A similar NK cell phenotype
is observed following acute HCMV infection in healthy indi-
viduals (72). Interestingly, modification of the NK cell surface
phenotype did not change with resolution of the infection (83),
thus suggesting a stable imprinting in the NK cell maturation
stage. Similar to what it has been observed in HCV and HIV-1
infections (33, 43), HCMV-reactivations in patients undergoing
umbilical cord blood transplantation induce the expansion of
the CD56neg/CD16pos/Siglec-7neg NK cell subset (60). The expan-
sion of anergic CD56neg NK cells following HCMV reactivation
likely occurs when T cell immunity is impaired and supports the
hypothesis that HCMV has a role in immune-senescence (85, 86).
Multiple components of the immune system are thus engaged
to protect the host from reactivating CMV replication. The sole
NK cell response is likely not sufficient in this regard and must act
in concert with recovering CMV-specific CD8pos T cells with the
support of CMV-specific CD4pos T cells. This is well demonstrated
in individuals infected with HIV, where the loss of antigen-specific
CD4pos T cells causes increased susceptibility to opportunistic
infections, including CMV reactivation (87). These data altogether
suggest that NK cells could be exploited together with CD8pos T
cells in the therapeutic treatment of CMV reactivation.
HCMV AND MEMORY NK CELLS
Studies in mice led to the demonstration that a population of
“memory”NK cells develop following acute infection with MCMV.
In particular, it has been reported that NK cells expressing the
activating Ly49H receptor undergo a clonal-like expansion upon
recognition of the MCMV-encoded m157 antigen and generate
long-lived memory NK cells (88). Similarly in humans, it has
been recently demonstrated that NKG2Cpos NK cells remarkably
increase in frequency following HCMV infection or reactivation
and can persist for years (60, 72, 89–92). Such expanded NKG2Cpos
NK cells may exert an efficient anti-viral activity by producing
higher amounts of cytokines, in particular IFN-γ, hence suggest-
ing that “memory-like” NK cell responses may occur in humans as
well. However, NKG2C cannot be considered as a univocal marker
of “memory-like” NK cells. Indeed, recent reports suggest that also
other NKRs that are preferentially found in terminally differenti-
ated NK cells, including activating KIRs or CD57, are up-regulated
following HCMV reactivation. In this context, a number of recent
studies suggest that the presence of activating KIRs correlates with
protection against viral infections (84, 93).
Despite “memory-like” NK cells mostly display a CD56dim/
CD16pos phenotype (60, 72), they have been shown to share
some phenotypic traits with CD56neg/CD16pos NK cells as well.
These similar traits between“memory-like”and CD56neg/CD16pos
NK cells are not supported by functional features, as the for-
mer are expected to display increased functional capacity while
the latter are well known to be impaired in a number of effec-
tor functions. Further studies are needed to confirm if the
KIRpos/NKG2Aneg/NKG2Cpos CD57pos NK cells represent the
human memory NK cell counterpart and to test whether they
share any of the CD56neg/CD16pos NK cell properties. Impor-
tantly, it would be interesting to determine whether continuous
stimulation of NK cells by persistent, but undetectable viral repli-
cation, in infected individuals plays a role in maintaining these
mature NK cell phenotypes.
CONCLUDING REMARKS
Viruses employ several strategies to escape from NK cell-mediated
clearance of virally infected cells or secretion of anti-viral
cytokines. In particular, it became clear that viruses are able
to affect the functional status and the homeostasis of NK cells
through the modulation/engagement of several surface receptors
and through the expansion of unconventional NK cell subsets.
Although many aspects of NK cell physiology have been disclosed
by taking lessons from the physiopathology of viral infections, sev-
eral fundamental questions still remain to be answered. First of all,
the origin and the expansion of the CD56neg NK cells subset that
represents the largest fraction of total NK cells in late stages of HIV-
1 infection and that highly contributes to the lack of viral control
and to disease progression. Disclosing the mechanisms underlying
the high frequencies of this highly anergic NK cell population is
key to better understand not only NK cell development but also to
make it possible the manipulation of these cells in vitro in order
to improve their anti-viral potential and provide a better control
of viral replication and spreading.
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